tiprankstipranks
Trending News
More News >
FORESIGHT AUTONOMOUS HOLDINGS LTD. (IL:FRSX)
:FRSX
Israel Market
Advertisement

Foresight (FRSX) AI Stock Analysis

Compare
4 Followers

Top Page

IL:FRSX

Foresight

(FRSX)

Select Model
Select Model
Select Model
Underperform 39 (OpenAI - 4o)
Rating:39Underperform
Price Target:
24.50
▼(-5.41% Downside)
Foresight's overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and declining revenues. Technical analysis indicates a bearish trend, while valuation metrics are unattractive due to negative earnings and lack of dividends. The absence of earnings call insights and corporate events leaves these areas unaddressed.

Foresight (FRSX) vs. iShares MSCI Israel ETF (EIS)

Foresight Business Overview & Revenue Model

Company DescriptionForesight (FRSX) is a technology-driven company focused on advancing the field of predictive analytics and decision-making solutions. The company operates within the sectors of big data analytics and artificial intelligence, offering core products that include software platforms designed to enhance operational efficiency and provide actionable insights across various industries. Foresight's innovative solutions cater to a range of applications, from supply chain optimization to risk management, enabling businesses to leverage data for improved outcomes.
How the Company Makes MoneyForesight generates revenue primarily through the sale of its software solutions and subscription services. The company offers various pricing models, including one-time licensing fees and recurring subscription fees for ongoing access to its platforms. Key revenue streams include direct sales to enterprise clients, partnerships with technology providers for integrated solutions, and consulting services that help clients implement and optimize their use of Foresight's products. Additionally, strategic partnerships with industry leaders enhance Foresight's market reach and can lead to revenue-sharing opportunities, further contributing to the company's earnings.

Foresight Financial Statement Overview

Summary
Foresight is facing significant financial challenges with negative net income, declining revenue, and negative EBIT and EBITDA margins. The balance sheet shows a weakening position with decreasing assets and equity, and cash flow analysis reveals negative free cash flow. These factors indicate substantial financial risks.
Income Statement
25
Negative
Foresight continues to face significant challenges on the income statement front, highlighted by negative net income and declining revenue. The gross profit margin for 2024 is approximately 60.55%, but the company experienced a revenue decline of 12.25% compared to the previous year. The EBIT and EBITDA margins are both negative, reflecting ongoing losses, which is a major concern for profitability and sustainability.
Balance Sheet
40
Negative
The balance sheet shows a weakening position with decreasing total assets and stockholders' equity. The debt-to-equity ratio stands at approximately 0.26, indicating manageable leverage. However, the return on equity is negative due to persistent losses. The equity ratio remains relatively stable, suggesting some degree of financial stability despite ongoing challenges.
Cash Flow
30
Negative
Cash flow analysis reveals a negative free cash flow, although there is a slight improvement in operating cash flow relative to net income. The company continues to rely on financing activities to support cash flow needs. The free cash flow to net income ratio is negative, indicating cash flow pressures.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue340.00K436.00K497.00K550.00K120.00K0.00
Gross Profit198.00K264.00K354.00K298.00K53.00K0.00
EBITDA-9.40M-12.48M-16.03M-17.24M-15.79M-12.58M
Net Income-9.19M-11.14M-18.41M-21.68M-15.04M-15.14M
Balance Sheet
Total Assets8.55M9.74M19.31M32.89M53.48M49.97M
Cash, Cash Equivalents and Short-Term Investments6.37M7.15M16.11M26.39M45.60M43.98M
Total Debt1.56M1.56M1.63M2.00M2.73M1.28M
Total Liabilities2.92M3.02M3.31M4.11M4.85M2.88M
Stockholders Equity5.93M6.07M15.39M28.33M48.41M47.02M
Cash Flow
Free Cash Flow-8.57M-11.12M-15.05M-17.37M-12.36M-11.54M
Operating Cash Flow-8.54M-11.05M-14.93M-17.06M-12.13M-11.49M
Investing Cash Flow-33.00K1.78M7.09M8.98M-12.58M85.00K
Financing Cash Flow1.00M903.00K4.18M0.0014.16M45.28M

Foresight Technical Analysis

Technical Analysis Sentiment
Positive
Last Price25.90
Price Trends
50DMA
26.73
Negative
100DMA
34.33
Negative
200DMA
54.40
Negative
Market Momentum
MACD
-0.30
Negative
RSI
51.36
Neutral
STOCH
15.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:FRSX, the sentiment is Positive. The current price of 25.9 is above the 20-day moving average (MA) of 25.76, below the 50-day MA of 26.73, and below the 200-day MA of 54.40, indicating a neutral trend. The MACD of -0.30 indicates Negative momentum. The RSI at 51.36 is Neutral, neither overbought nor oversold. The STOCH value of 15.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:FRSX.

Foresight Risk Analysis

Foresight disclosed 42 risk factors in its most recent earnings report. Foresight reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Foresight Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
49
Neutral
61.98M14.39%-1797.14%
45
Neutral
38.75M-23.68%31.97%
42
Neutral
159.45M-9.08238.35%-0.43%
39
Underperform
30.49M-13.19%57.46%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IL:FRSX
Foresight
25.50
-33.30
-56.63%
IL:SCDX
Scodix
262.50
-43.60
-14.24%
IL:PHTM
Photomyne
2,320.00
-462.00
-16.61%
IL:NRGN
Nrgene
295.00
-1.90
-0.64%
IL:UTRN
Utron
497.10
102.00
25.82%
IL:RZR
Razor Labs
372.00
-269.80
-42.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 27, 2025